Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index
- PMID: 31009501
- PMCID: PMC6476532
- DOI: 10.1371/journal.pone.0215662
Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index
Abstract
Although breast cancer mortality is decreasing, morbidity following treatment remains a significant issue, as patients face symptoms such as cancer-related fatigue (CRF). The aim of the present study is to develop a classification system that monitors fatigue via integration of an objective clinical assessment with patient self-report. Forty-three women participated in this research. Participants were post-treatment breast cancer survivors who had been surgically treated for their primary tumour with no evidence of neoplastic disease at the time of recruitment. Self-perceived fatigue was assessed with the Spanish version of the Piper Fatigue Scale-Revised (R-PFS). Objective fatigue was assessed by the 30 second Sit-to-Stand (30-STS) test. Confirmatory factor analysis was done with Maximum Likelihood Extraction (MLE). Internal consistency was obtained by Cronbach's α coefficients. Bivariate correlation showed that 30-STS performance was negatively-inversely associated with R-PFS. The MANOVA model explained 54.3% of 30-STS performance variance. Using normalized scores from the MLE, a classification system was developed based on the quartiles. This study integrated objective and subjective measures of fatigue to better allow classification of patient CRF experience. Results allowed development of a classification index to classify CRF severity in breast cancer survivors using the relationship between 30-STS and R-PFS scores. Future research must consider the patient-perceived and clinically measurable components of CRF to better understand this multidimensional issue.
Conflict of interest statement
This research project was partially funded by Contract Nº PS16060 in IBIMA between Novartis-IBIMA (Traslation Research in Cancer B-01 & Clinimetric F-14). This consisted on a payment for author CRJ as physical therapist in the assessment. There is no other relationship with Novartis as partial funder apart from defraying the expenses of employment, and there are no patents, products in development or marketed products relationship to declare according to the definition of financial competing interest given by Plos One.
References
-
- National Cancer Institute. Office of Cancer Survivorship. [Internet]. [cited 29 Jan 2019]. Available: https://cancercontrol.cancer.gov/ocs/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
